research Oral Janus Kinase Inhibitors for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
Search
for
Sort by
Research
120-150 / 1000+ results
research Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
AA patients with comorbid conditions face more severe hair loss and need specific treatments.
research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research Observation and Consideration on Using of JAKi in Clinical Trials in Times of COVID-19
Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
research A Description of Alopecia Areata in European Patients Based on Real-World Survey Data: Physician-Reported Characterization of Severity and Associated Treatment Utilization
More effective treatments are needed for severe alopecia areata.
research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Topical Tofacitinib for the Treatment of Alopecia Areata Affecting Facial Hair
Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
research Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
Ruxolitinib helped a man regrow his beard after years of hair loss.
research Ruxolitinib Found to Cause Eyelash Growth: A Case Report
Ruxolitinib treatment may cause eyelash growth.
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research Alopecia – New Building Blocks
New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
research A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
research Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Successful Treatment of Alopecia Totalis with Tofacitinib in a Danish Patient
A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Treatment of Severe Alopecia Areata with Baricitinib
Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
research Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Alopecia Areata Triggered by Psychological Stress and Successfully Treated with a Janus Kinase Inhibitor: Case Report
Stress-related hair loss was reversed with a special medication.
research Case Report: Alopecia Areata Universalis Successfully Treated with Baricitinib
Baricitinib successfully treated severe hair loss.
research Effectiveness of Oral Tofacitinib Treatment on Patients With Moderate-to-Severe Alopecia Areata in Iran
Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
research The Use of Tofacitinib in the Treatment of Immune-Mediated Universal Alopecia in a Patient with Systemic Lupus Erythematosus: A Case Report
Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
research Tyrosine Kinase Inhibitors in Dermatology: A Systematic Review
Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
research Clinical Case of Tofacitinib Therapy in Autoimmune Alopecia in Patient with Ulcerative Colitis
Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
research An Urticarial Drug Eruption Caused by Tofacitinib for Alopecia Universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.